Targeted hypothermia versus targeted normothermia after out-of-hospital cardiac arrest: a statistical analysis plan
Janus Christian Jakobsen,
Josef Dankiewicz,
Theis Lange,
Tobias Cronberg,
Gisela Lilja,
Helena Levin,
Jan Bělohlávek,
Clifton Callaway,
Alain Cariou,
David Erlinge,
Jan Hovdenes,
Michael Joannidis,
Per Nordberg,
Mauro Oddo,
Paolo Pelosi,
Hans Kirkegaard,
Glenn Eastwood,
Christian Rylander,
Manoj Saxena,
Christian Storm,
Fabio Silvio Taccone,
Matthew P. Wise,
Matt P. G. Morgan,
Paul Young,
Alistair Nichol,
Hans Friberg,
Susann Ullén,
Niklas Nielsen
Affiliations
Janus Christian Jakobsen
Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital
Josef Dankiewicz
Department of Clinical Sciences, Cardiology, Lund University, Skåne University Hospital
Theis Lange
Section of Biostatistics, Faculty of Health and Medical Sciences, University of Copenhagen
Tobias Cronberg
Department of Clinical Sciences, Neurology, Lund University, Skåne University Hospital
Gisela Lilja
Department of Clinical Sciences, Neurology, Lund University, Skåne University Hospital
Helena Levin
Department of Clinical Sciences, Research and Education, Lund University, Skåne University Hospital
Jan Bělohlávek
2nd Department of Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital
Clifton Callaway
Department of Emergency Medicine, University of Pittsburgh
Alain Cariou
Medical Intensive Care Unit, Cochin University Hospital (APHP) and Paris Descartes University
David Erlinge
Department of Clinical Sciences, Cardiology, Lund University, Skåne University Hospital
Jan Hovdenes
Department of Anesthesia and Intensive Care, Oslo University Hospital, Rikshospitalet
Michael Joannidis
Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck
Per Nordberg
Department of Medicine, Center for Resuscitation Science, Karolinska Institute
Mauro Oddo
Department of Intensive Care Medicine, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois (CHUV) - University Hospital, University of Lausanne
Paolo Pelosi
Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa
Hans Kirkegaard
Research Center for Emergency Medicine, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University
Glenn Eastwood
Department of Intensive Care, Austin Hospital
Christian Rylander
Department of Anesthesiology and Intensive Care Medicine, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg
Manoj Saxena
Bankstown Hospital Clinical School and The George Institute for Global Health, University of New South Wales
Christian Storm
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin
Fabio Silvio Taccone
Department of Intensive Care, Erasme University Hospital, Université Libre de Bruxelles (ULB)
Matthew P. Wise
Adult Critical Care, University Hospital of Wales
Matt P. G. Morgan
Adult Critical Care, University Hospital of Wales
Paul Young
Medical Research Institute of New Zealand
Alistair Nichol
University Collage Dublin-Clinical Research Centre, St Vincent’s University Hospital
Hans Friberg
Department of Clinical Sciences, Anesthesia & Intensive Care, Lund University, Skåne University Hospital
Susann Ullén
Clinical Studies Sweden, Skåne University Hospital
Niklas Nielsen
Department of Clinical Sciences Lund, Anesthesia & Intensive Care, Lund University, Helsingborg Hospital
Abstract Background To date, targeted temperature management (TTM) is the only neuroprotective intervention after resuscitation from cardiac arrest that is recommended by guidelines. The evidence on the effects of TTM is unclear. Methods/design The Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2) trial is an international, multicentre, parallel group, investigator-initiated, randomised, superiority trial in which TTM with a target temperature of 33 °C after cardiac arrest will be compared with a strategy to maintain normothermia and active treatment of fever (≥ 37.8 °C). Prognosticators, outcome assessors, the steering group, the trial coordinating team, and trial statisticians will be blinded to treatment allocation. The primary outcome will be all-cause mortality at 180 days after randomisation. We estimate a 55% mortality in the targeted normothermia group. To detect an absolute risk reduction of 7.5% with an alpha of 0.05 and 90% power, 1900 participants will be enrolled. The secondary neurological outcome will be poor functional outcome (modified Rankin scale 4–6) at 180 days after cardiac arrest. In this paper, a detailed statistical analysis plan is presented, including a comprehensive description of the statistical analyses, handling of missing data, and assessments of underlying statistical assumptions. Final analyses will be conducted independently by two qualified statisticians following the present plan. Discussion This SAP, which was prepared before completion of enrolment, should increase the validity of the TTM trial by mitigation of analysis-bias.